SAFETY AND EFFICACY OF VANDETANIB AS SYSTEMIC TREATMENT FOR PATIENTS WITH ADVANCED AND PROGRESSIVE MEDULLARY THYROID CANCER (MTC)

被引：0

作者：

Grande, E. ^{[1
]}

Martinez-Trufero, J. ^{[2
]}

Arevalo, S. ^{[3
]}

Alvarez-Escola, C. ^{[4
]}

Beltran, M. ^{[5
]}

Jimenez Fonseca, P. ^{[6
]}

Alonso-Gordoa, T. ^{[1
]}

Dalmau, E. ^{[7
]}

Duran, M. ^{[8
]}

Gallegos, I. ^{[9
]}

Manzano, J. L. ^{[10
]}

Mesia, R. ^{[11
]}

Pajares, I. ^{[12
]}

Fuentes, J. ^{[13
]}

Grau, J. J. ^{[14
]}

Reig Torras, O. ^{[14
]}

Trigo, J. M. ^{[15
]}

Pelaez, B. ^{[16
]}

Zafon, C. ^{[17
]}

Capdevila, J. ^{[18
]}

机构：

[1] Ramon & Cajal Univ Hosp, Med Oncol Dept, Madrid, Spain

[2] HU Miguel Servet, Zaragoza, Spain

[3] Hosp Donostia, Med Oncol Dept, San Sebastian, Spain

[4] La Paz Univ Hosp, Dept Endocrinol, Madrid, Spain

[5] ICO Girona, Girona, Spain

[6] Hosp Univ Cent Asturias, Serv Oncol Med, Oviedo, Spain

[7] Corp Hosp Parc Tauli, Sabadell, Spain

[8] Hosp Rey Juan Carlos, Mostoles, Spain

[9] Hosp Gen Segovia, Serv Oncol Med, Segovia, Spain

[10] ICO Hosp Germans Trias & Pujol, Barcelona, Spain

[11] Inst Catala Oncol ICO Hosp, IDIBELL Head & Neck Canc Unit, Med Oncol Dept, Barcelona, Spain

[12] Hosp Clin Lozano Blesa, Zaragoza, Spain

[13] Hosp Valme, Seville, Spain

[14] Hosp Clin Barcelona, Barcelona, Spain

[15] Hosp Univ Virgen de la Victoria, Malaga, Spain

[16] Univ Hosptial Valladolid, Valladolid, Spain

[17] Vall de Hebron Univ Hosp, Endocrinol Dept, Barcelona, Spain

[18] Vall dHebron Univ Hosp, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1161P

引用

页数：1

共 50 条

[41] Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients
Zheng, Xiangqian
Fang, Meiyu
Fan, Yun
Sun, Yuping
Sun, Meili
Yang, Ankui
Zhang, Bin
Liu, Qinjiang
Liu, Hui
Zhou, Xiaohong
Huang, Tao
Qin, Jianwu
Wang, Zhaohui
Qin, Mengmeng
Shen, Zhenwei
Yao, Sheng
Yang, Jason
Wang, Yu
Gao, Ming
ENDOCRINE-RELATED CANCER, 2024, 31 (04)
[42] Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort
Chougnet, Cecile N.
Borget, Isabelle
Leboulleux, Sophie
de la Fouchardiere, Christelle
Bonichon, Francoise
Criniere, Lise
Niccoli, Patricia
Bardet, Stephane
Schneegans, Olivier
Zanetta, Sylvie
Schvartz, Claire
Drui, Delphine
Chauffert, Bruno
Rohmer, Vincent
Schlumberger, Martin
THYROID, 2015, 25 (04) : 386 - 391
[43] TREATMENT WITH VANDETANIB IN A 11 YEARS OLD BOY WITH ADVANCED MEDULLARY THYROID CARCINOMA
Papendieck, Patricia
Vieites, Ana
Elias, Eugenia
Garcia Lombardi, Mercedes
Chiesa, Ana
HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 596 - 596
[44] Role of vandetanib in the management of medullary thyroid cancer
Brassard, Maryse
Rondeau, Genevieve
BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 59 - 66
[45] Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome
Pitoia, Fabian
Bueno, Fernanda
Schmidt, Angelica
Lucas, Sabrina
Cross, Graciela
ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2015, 59 (04): : 343 - 346
[46] Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
Enrique Grande
Michael C. Kreissl
Sebastiano Filetti
Kate Newbold
Walter Reinisch
Caroline Robert
Martin Schlumberger
Lærke K. Tolstrup
Jose L. Zamorano
Jaume Capdevila
Advances in Therapy, 2013, 30 : 945 - 966
[47] Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
Grande, Enrique
Kreissl, Michael C.
Filetti, Sebastiano
Newbold, Kate
Reinisch, Walter
Robert, Caroline
Schlumberger, Martin
Tolstrup, Laerke K.
Zamorano, Jose L.
Capdevila, Jaume
ADVANCES IN THERAPY, 2013, 30 (11) : 945 - 966
[48] VANDETANIB IN LOCALLY ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC): A RANDOMIZED, DOUBLE-BLIND PHASE III TRIAL (ZETA)
Wells, S. A.
Robinson, B. G.
Gagel, R. F.
Dralle, H.
Fagin, J. A.
Santoro, M.
Baudin, E.
Vasselli, J.
Read, J.
Schlumberger, M.
ANNALS OF ONCOLOGY, 2010, 21 : 315 - 315
[49] Treatment of advanced medullary thyroid cancer
Smit J.
Thyroid Research, 6 (Suppl 1)
[50] Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
Werner, R. A.
Schmid, J. S.
Muegge, D. O.
Lueckerath, K.
Higuchi, T.
Haenscheid, H.
Grelle, I.
Reiners, C.
Herrmann, K.
Buck, A. K.
Lapa, C.
MEDICINE, 2015, 94 (45) : e2016

← 1 2 3 4 5 →